Research and Markets: Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2012

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/5a995a/sudan_and_south_su) has announced the addition of the "Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2012 `" report to their offering.

BMI maintains its view that the outlook for Sudan and South Sudan's pharmaceutical markets will be more dependent on the economic and political stability of the two countries, rather than their need for medicines. With the most recent Sudanese civil war ended in 2005 after more than 20 years of fighting, tension remains high and violent clashes between forces in South Sudan and its northern neighbour continue. It is clear that the market will not be able to attract significant interest from multinational companies for at least half a decade. Market pioneers are likely to be non-Western, small generic drugmakers. Larger firms may be able to increase their exposure to market with deals with local distributors or sell bulk products that can be repackaged and sold on. In the next few years, drug expenditure is likely to remain erratic. Over the longer term, improved access to medicines and demand for more advanced pharmaceuticals will remain at an elevated growth rate.

Sudan and South Sudan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Sudan and South Sudan's pharmaceuticals and healthcare industry.

Headline Expenditure Projections:

• Pharmaceuticals: SDG1.49bn (US$563mn) in 2011 to SDG1.68bn (US$571mn) in 2012; +12.9% in local currency terms with a 1.4% in US dollar terms. High in local currency terms due to elevated inflation but weaker growth in US dollar terms due to the expectation of further depreciation of the Sudanese pound.
• Healthcare: SDG13.07bn (US$4.93mn) in 2011 to SDG15.16bn (US$5.14bn) in 2012; +16.0% in local currency terms and 4.2% in US dollar terms.

Key Topics Covered:

• BMI Industry View
• Pharmaceutical Business Environment Ratings
• Rewards
• Risks
• Market Summary
• Regulatory Regime
• Industry Forecast Scenario
• Assessing The Value Of Sudan And South Sudan's Pharmaceutical Market
• Pharmaceutical Market Forecast
• Industry Developments
• Healthcare Market Forecast
• Key Growth Factors - Macroeconomic
• Industry Risk/Reward Ratings (RRRs)

For more information visit http://www.researchandmarkets.com/research/5a995a/sudan_and_south_su